BACKGROUND: Sentinel node biopsy (SNB) has evolved as the standard of care in the surgical staging of breast cancer. This technique is accurate for surgical staging of axillary nodal disease. We hypothesized that axillary recurrence after SNB is rare and that SNB may provide regional control in patients with microscopic nodal involvement. METHODS: With institutional review board approval, SNB was performed with peritumoral injection of 99mTc-labeled sulfur colloid. From 1996 to 2003, 1167 patients were entered into a prospective cancer database after surgical therapy; 916 patients consented to long-term follow-up. Fifty-two patients (5.7%) did not map successfully and were excluded, leading to a study population of 864 patients. The median follow-up was 27.4 months (range, 1-98 months). RESULTS: The median number of sentinel nodes harvested was 2, and 633 (73%) patients had negative sentinel nodes. Thirty (4.7%) of those sentinel node-negative patients underwent completion axillary dissection, whereas 592 (94%) patients were followed up with observation. A total of 231 (27%) had positive sentinel nodes: 158 (68%) of these patients underwent completion axillary dissection, and 73 (32%) were managed with observation alone. Two (.32%) patients who were sentinel node negative had an axillary recurrence; one of these patients had undergone completion axillary dissection. No patient in the observed sentinel node-positive group had an axillary recurrence (odds ratio, .37; P = .725). CONCLUSIONS: On the basis of a median follow-up of 27.4 months, axillary recurrence after SNB is extraordinarily rare regardless of nodal involvement, thus indicating that this technique provides an accurate measure of axillary disease and may impart regional control for patients with node-positive disease.
BACKGROUND: Sentinel node biopsy (SNB) has evolved as the standard of care in the surgical staging of breast cancer. This technique is accurate for surgical staging of axillary nodal disease. We hypothesized that axillary recurrence after SNB is rare and that SNB may provide regional control in patients with microscopic nodal involvement. METHODS: With institutional review board approval, SNB was performed with peritumoral injection of 99mTc-labeled sulfur colloid. From 1996 to 2003, 1167 patients were entered into a prospective cancer database after surgical therapy; 916 patients consented to long-term follow-up. Fifty-two patients (5.7%) did not map successfully and were excluded, leading to a study population of 864 patients. The median follow-up was 27.4 months (range, 1-98 months). RESULTS: The median number of sentinel nodes harvested was 2, and 633 (73%) patients had negative sentinel nodes. Thirty (4.7%) of those sentinel node-negative patients underwent completion axillary dissection, whereas 592 (94%) patients were followed up with observation. A total of 231 (27%) had positive sentinel nodes: 158 (68%) of these patients underwent completion axillary dissection, and 73 (32%) were managed with observation alone. Two (.32%) patients who were sentinel node negative had an axillary recurrence; one of these patients had undergone completion axillary dissection. No patient in the observed sentinel node-positive group had an axillary recurrence (odds ratio, .37; P = .725). CONCLUSIONS: On the basis of a median follow-up of 27.4 months, axillary recurrence after SNB is extraordinarily rare regardless of nodal involvement, thus indicating that this technique provides an accurate measure of axillary disease and may impart regional control for patients with node-positive disease.
Authors: Julia Park; Jane V Fey; Arpana M Naik; Patrick I Borgen; Kimberly J Van Zee; Hiram S Cody Journal: Ann Surg Date: 2007-03 Impact factor: 12.969
Authors: Igor Langer; Ulrich Guller; Carsten T Viehl; Holger Moch; Edward Wight; Felix Harder; Daniel Oertli; Markus Zuber Journal: Indian J Surg Oncol Date: 2010-08-07
Authors: Armando E Giuliano; Linda McCall; Peter Beitsch; Pat W Whitworth; Peter Blumencranz; A Marilyn Leitch; Sukamal Saha; Kelly K Hunt; Monica Morrow; Karla Ballman Journal: Ann Surg Date: 2010-09 Impact factor: 12.969
Authors: Haejin In; Bridget A Neville; Stuart R Lipsitz; Katherine A Corso; Jane C Weeks; Caprice C Greenberg Journal: Ann Surg Date: 2012-05 Impact factor: 12.969
Authors: Marieke E Straver; Philip Meijnen; Geertjan van Tienhoven; Cornelis J H van de Velde; Robert E Mansel; Jan Bogaerts; Nicole Duez; Luigi Cataliotti; Jean H G Klinkenbijl; Helen A Westenberg; Huub van der Mijle; Marko Snoj; Coen Hurkmans; Emiel J T Rutgers Journal: Ann Surg Oncol Date: 2010-03-19 Impact factor: 5.344
Authors: Jacqueline S Jeruss; Lisa A Newman; Gregory D Ayers; Massimo Cristofanilli; Kristine R Broglio; Funda Meric-Bernstam; Min Yi; Jennifer F Waljee; Merrick I Ross; Kelly K Hunt Journal: Cancer Date: 2008-06-15 Impact factor: 6.860